Investigation of roots extracts Pseudrocedrela kotschyi and Trichilia emetica led to
identification of 5 limonoid derivatives, Kotschyins D–H, and 11 known compounds. Their …

Histone deacetylase inhibitors (HDACi) have been enthusiastically investigated as a novel
generation of chemotherapeutics for cancers usually called as epigenetic therapeutics …

Histone deacetylases (HDACs) are common targets for cancer therapy as they are
expressed in many forms of cancers; several research studies have been introduced …

Highlights•The histone deacetylase (HDAC) inhibitor Scriptaid inhibits multiple myeloma
(MM) cell proliferation and cycle.•Scriptaid induces MM cell apoptosis.•p21 is the key …

Cancer cells with stem cell characteristics are harbored by most tumors, and are
characterized by epithelial–mesenchymal transition (EMT)–which promotes invasive growth …

Previous studies have shown that histone deacetylase (HDAC) inhibitors stimulate
osteoblast differentiation in vitro and bone formation in vivo. However, the effects of HDAC …

Abexinostat is a pan histone deacetylase inhibitor (HDACi) that demonstrates efficacy in
malignancy treatment. Like other HDACi, this drug induces a profound thrombocytopenia …

MicroRNAs (miRNAs) are important post-transcriptional regulators involved in many
biological processes. We investigated the expression profiles of miRNAs affected by the …

Histone deacetylase (HDAC) inhibitors are a new class of anticancer agents that act by
inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell lines. To …

Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of
drugs for treatment of cancers, especially subcutaneous T-cell lymphoma. In this study, we …